Accessibility Menu
Bio-Gene Technology logo

Bio-Gene Technology(ASX) BGT

Market CapA$9.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-89%
5 Year-86%
1 Year+5%
1 Month+29%
A$0.02
+0.00%
+0.00Today
Bio-Gene Technology last closing stock price
MetricPriceDate
Last closeAUD 0.022026-08-13
Bio-Gene Technology stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.35%AUD 0.022026-08-06
1 month+29.41%AUD 0.022026-07-13
3 month-21.43%AUD 0.032026-05-15
Year to date-4.35%AUD 0.022025-12-29
1 year+4.76%AUD 0.022025-08-11
3 year-76.84%AUD 0.102023-08-14
5 year-86.03%AUD 0.162021-08-13
Since inception-89%AUD 0.202017-11-29

Bio-Gene Technology Financials at a Glance

Market Cap

A$9.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

-A$435.00

Net Income (TTM)

-A$4.33M

EPS (TTM)

-A$0.01

P/E Ratio

-2.32

Dividend

A$0.00

Beta (Volatility)

-0.02 (Low)

Price

A$0.02

Volume

100

Open

A$0.02

Previous Close

A$0.02

Daily Range

A$0.02 - A$0.02

52-Week Range

A$0.02 - A$0.06

Estimated Earnings Date

Sep 1, 2026

BGT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bio-Gene Technology

Bio-Gene Technology Limited is an Australian agricultural technology firm focused on developing and commercializing innovative insecticides and pesticides. The company aims to provide effective solutions for animal health, crop protection, public health, and consumer applications.

Products and Services
  • Flavocide, an insecticide utilizing beta-triketone technology
  • Qcide, a natural oil derived from eucalyptus cloeziana
  • Research partnerships to enhance product effectiveness and production
Growth Outlook
  • Partnerships with BASF and research organizations enhance product development
  • Focus on expanding Qcide oil production through tissue culture systems
  • Potential market growth in agricultural inputs sector driven by innovation
Financial Highlights
  • Recent quarterly revenue of 18,755 AUD, indicating product traction
  • Cash and short-term investments of 1,080,979 AUD as of December 2025
  • Current ratio of 4.31, reflecting strong liquidity position
Bio-Gene Technology Limited operates in a competitive agricultural inputs industry, leveraging advanced technology to create sustainable solutions. The company's flagship products, Flavocide and Qcide, are positioned to meet the growing demand for environmentally friendly pest control options. Collaborations with established partners like BASF and academic institutions enhance the company's research capabilities, paving the way for future innovations. Financially, the company has shown resilience with a solid cash position, allowing for continued investment in research and development. The current ratio indicates a strong ability to cover short-term liabilities, which is crucial for ongoing operations. As the agricultural sector increasingly shifts towards sustainable practices, Bio-Gene Technology Limited is well-positioned to capitalize on emerging opportunities.
AI Generated • Aug 5, 2026

Industry

Chemicals

Sector

Materials

CEO

Tim Grogan

Headquarters

Melbourne, VIC 3000, AU

BGT Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-140.35%

Return on Capital

-182.75%

Return on Assets

-132.96%

Earnings Yield

-43.10%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$9.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

438.06M

Volume

100

Avg. Volume

451.20K

Financials (TTM)

Gross Profit

-A$606.07K

Operating Income

-A$7.61M

EBITDA

-A$5.73M

Operating Cash Flow

-A$3.66M

Capital Expenditure

-A$3.90K

Free Cash Flow

-A$3.67M

Cash & ST Invst.

A$1.08M

Total Debt

A$0.00

Bio-Gene Technology Performance Analysis

Bio-Gene Technology annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 445,726N/A
20232023-06-30AUD 149,232-66.5%
20242024-06-30AUD 18,320-87.7%
20252025-06-30AUD 0N/A
Bio-Gene Technology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-102.3%
Q22024-12-31100.0%
Q42025-06-30N/A
Q22025-12-31N/A
Bio-Gene Technology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.02N/A
20232023-06-30AUD -0.02-3.2%
20242024-06-30AUD -0.01-29.3%
20252025-06-30AUD -0.01-6.2%
Bio-Gene Technology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3044.0%
Q22024-12-31-55.3%
Q42025-06-3065.8%
Q22025-12-31-84.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

-A$20.85K

+87.8%

Gross Margin

0.00%

N/A

Market Cap

A$9.64MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$1.93M

N/A

Employees

5

N/A

Net Income

-A$1.40M

+7.2%

EBITDA

-A$2.77M

-80.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$1.08M

-66.5%

Total Debt

A$0.00

N/A

Accounts Receivable

A$29.28K

-94.8%

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

N/A

Short Term Debt

A$0.00

N/A

Return on Assets

-1.33%

N/A

Return on Invested Capital

-3.73%

N/A

Free Cash Flow

-A$946.61K

+45.8%

Operating Cash Flow

-A$946.61K

+45.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VBS.AXVectus Biosystems Limited
A$0.16+0.00%
IXC.AXInvex Therapeutics Ltd
A$0.12+0.00%
ICR.AXIntelicare Holdings Limited
A$0.03+0.00%
ACR.AXAcrux Limited
A$0.01-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About BGT

What is the current price of Bio-Gene Technology?

Bio-Gene Technology is trading at A$0.02 per share.

What is the 52-week range for Bio-Gene Technology?

Over the past 52 weeks, Bio-Gene Technology has traded between A$0.02 and A$0.06.

How much debt does Bio-Gene Technology have?

As of the most recent reporting period, Bio-Gene Technology reported total debt of A$51.21K.

How much cash does Bio-Gene Technology have on hand?

Bio-Gene Technology reported A$638.34K in cash and cash equivalents in its most recent financial results.

What is Bio-Gene Technology’s dividend yield?

Bio-Gene Technology does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.